SCHEMBL10243064

SCHEMBL10243064

COC(=O)Cc1cccc(NCCCOc2cccc3cccnc23)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.52
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 4/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
GAA P10253 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
GLRA3 O75311 2/20 0.46
MAPT P10636 3/20 0.46
GLRB P48167 1/20 0.45
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
SYK P43405 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243088 0.84 POLB (0.53) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL10243087 0.82 POLB (0.67) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL10243092 0.78 ALDH1A1 (0.47) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL10243353 0.77 MEN1 (0.47) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL12028671 0.75 SLC7A5 (0.46) MEN1KMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL11935002 0.73 SLC7A5 (0.47) MEN1KMT2AALDH1A1SMN1; SMN2GAA
SCHEMBL3453971 0.72 KDM4E (0.64) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL12028667 0.72 SLC7A5 (0.48) KMT2AALDH1A1KDM4ESMN1; SMN2LMNA
SCHEMBL1115580 0.71 MAPT (0.62) POLBMEN1KMT2AALDH1A1KDM4E
SCHEMBL1115678 0.70 MAPT (0.60) POLBMEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 POLB 3348/4885MEN1 2456/4885KMT2A 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.